title: [Past, present and future of obesity pharmacotherapy].
abstract: Obese (BMI > or = 30 kg/m2) and overweight (BMI > or = 25 and < 30 kg/m2) individuals are at high risk of developing serious chronic health problems, including type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease. Caloric restriction, increased physical activity and behavioral therapy remain the primary treatment options for the management of body weight in these individuals. When a weight loss of 5-10% cannot be achieved in 3-6 months by lifestyle changes drug therapy might be indicated. This review will provide a brief history of obesity pharmacotherapy, discuss the status of currently available obesity drugs and outline the future drug development. A medical need exists for the development of novel weight loss therapies or combinations of known therapies.
authors.affiliation: Metabol KLINIK s.r.o., Ambulancia pre diabetológiu, poruchy Iátkovej premeny a výzivy, Bratislava, Slovenská republika. lfabryova@metabolklinik.sk
authors.forename: L'ubomíra
authors.initials: L
authors.lastname: Fábryová
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000188:drug therapy*
chemical_list: D019440:Anti-Obesity Agents